Status:
COMPLETED
Impact of SGLT2 on Glucosuria in HNF1A-MODY
Lead Sponsor:
Steno Diabetes Center Copenhagen
Collaborating Sponsors:
University of Copenhagen
Conditions:
Maturity-Onset Diabetes of the Young, Type 3
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Maturity onset diabetes of the young (MODY) is a subtype of diabetes which is caused by mutations in specific genes leading to diabetes. The most common cause of MODY is due to mutations in the gene h...
Detailed Description
Participants: Patients with HNF1A-MODY (n=12) and patients with T2D (n=12)
Eligibility Criteria
Inclusion
- Age ≥18 years
- HNF1A-MODY verified by genetic testing (only patients with HNF1A-MODY)
- Type 2 diabetes diagnosis according to World Health Organization (only patients with type 2 diabetes)
- Treatment with diet and/or a glucose-lowering drug (only patients with HNF1A-MODY)
- Normal haemoglobin (males 8.3-10.5 mmol/l, females 7.3-9.5 mmol/l)
- Informed consent
Exclusion
- Nephropathy (estimated GFR \<60 ml/min/1.73m2 and/or albuminuria)
- Known significant liver disease and/or plasma alanine aminotransferase (ALT) and/or plasma aspartate aminotransferase (AST) above 2 × normal values)
- Pregnancy or breastfeeding
- Treatment with SGLT2 inhibitor
- Fasting plasma glucose \> 10 mmol/l
- Family history of HNF1A-MODY (only patients with type 2 diabetes)
Key Trial Info
Start Date :
June 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 14 2023
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT05417646
Start Date
June 22 2022
End Date
June 14 2023
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Steno Diabetes Center Copenhagen
Herlev, Denmark, 2730